BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 15,720,000 shares, a decrease of 9.1% from the December 31st total of 17,290,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is currently 7.7 days.

Institutional Trading of BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in BCRX. Venturi Wealth Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $48,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. KBC Group NV lifted its position in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 4,537 shares during the period. Finally, Quantinno Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $82,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $7.90 on Friday. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -12.95 and a beta of 1.76. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The business’s fifty day moving average price is $7.63 and its two-hundred day moving average price is $7.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period in the previous year, the business posted ($0.19) earnings per share. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. As a group, research analysts forecast that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on BCRX. Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Evercore ISI raised their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.